87
Views
21
CrossRef citations to date
0
Altmetric
Original Research

Switching to preservative-free latanoprost: impact on tolerability and patient satisfaction

, &
Pages 557-566 | Published online: 21 Mar 2017

References

  • European Glaucoma Society Guidelines Fourth Edition Available from: http://www.eugs.org/eng/EGS_guidelines4.aspAccessed July 1, 2015
  • BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmol200886771672618537937
  • BaudouinCLabbéALiangHPaulyABrignole-BaudouinFPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
  • ReardonGKotakSSchwartzGFObjective assessment of compliance and persistence among patients treated for glaucoma and ocular hypertension: a systematic reviewPatient Prefer Adherence2011544146322003282
  • YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm20091572874019954264
  • AriasASchargelKUssaFCanutMIRoblesAYSánchezBMPatient persistence with first-line antiglaucomatous monotherapyClin Ophthalmol2010426126720463793
  • International Epidemiological Association IEA Good Epidemiological Practice (GEP) Available from: http://ieaweb.org/good-epidemiological-practice-gep/Accessed January 1, 2017
  • CucheratMStalmansIRoulandJFRelative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted indirect comparison meta-analysis of randomized clinical trialsJ Glaucoma2014231e69e7523881267
  • PisellaPJPouliquenPBaudouinCPrevalence of ocular symptoms and signs with preserved and preservative free glaucoma medicationBr J Ophthalmol20028641842311914211
  • JaenenNBaudouinCPouliquenPManniGFigueiredoAZeyenTOcular symptoms and signs with preserved and preservative-free glaucoma medicationsEur J Ophthalmol20071734134917534814
  • LemijHGHoevenaarsJGvan der WindtCBaudouinCPatient satisfaction with glaucoma therapy: reality or myth?Clin Ophthalmol2015978579325999687
  • AlmALatanoprost in the treatment of glaucomaClin Ophthalmol201481967198525328381
  • RoulandJFTraversoCEStalmansIFekihLEDelvalLRenaultDBaudouinCT2345 Study GroupEfficacy and safety of preservative-free latanoprost eyedrops, compared with BAK-preserved latanoprost in patients with ocular hypertension or glaucomaBr J Ophthalmol201397219620023203707
  • KaštelanSTomićMMetež SoldoKSalopek-RabatićJHow ocular surface disease impacts the glaucoma treatment outcomeBiomed Res Int2013201369632824224176
  • DrewTWolffsohnJSUsability of prostaglandin monotherapy eye droppersBr J Ophthalmol20159991251125425761745
  • LeeAJMcCluskeyPClinical utility and differential effects of pros-taglandin analogs in the management of raised intraocular pressure and ocular hypertensionClin Ophthalmol2010474176420689791
  • KonstasAGMaskalerisGGratsonidisSSardelliCCompliance and viewpoint of glaucoma patients in GreeceEye (Lond)200014Pt 575275611116698